Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 10, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Executive Supplemental Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
Changes in share interests were reported for four individuals following the re-investment of dividends paid on April 6, 2006. The transactions occurred at a price of $51.87 per share. The specific increases in Ordinary Share ADRs were:
- Dr F Calhoun: 376.350 shares
- Dr J P Garnier: 365.125 shares
- Mr D Stout: 299.566 shares
- Dr T Yamada: 234.938 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a routine disclosure of director shareholding changes in compliance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Confirm the dividend reinvestment price of $51.87 per share.
- Verify the specific share count increases for the named directors.
- Note that this filing does not contain financial performance data for the period.